Remternetug

Remternetug (LY3372993) is Eli Lilly's follow-up to Kisunla (donanemab), an anti-amyloid antibody hitting the same pyroglutamate-modified amyloid beta epitope but engineered for subcutaneous self-injection instead of IV infusion [1]. The Phase 3 TRAILRUNNER-ALZ 1 study (NCT05463731, n≈1,667) enrolled early symptomatic Alzheimer's patients with amyloid plaque clearance as the primary endpoint and finished blinded treatment in June 2024, with topline read expected around H1 2026 [2][10]. In parallel, the DIAN-TU-002 platform (NCT06647498) runs remternetug in dominantly inherited AD, one of the highest-conviction genetic populations in neurology [3]. If the subQ delivery works and the amyloid-clearance signal holds, this is how Lilly turns a $65B revenue franchise into a chronic, at-home Alzheimer's therapy instead of an infusion-center product [4].

Remternetug is a novel biologic in late-stage development, with Phase 3 as the highest active phase. TRAILRUNNER-ALZ 1 (NCT05463731) is the Phase 3 amyloid-clearance study in early symptomatic AD, ~1,667 participants across a 600-patient double-blind primary cohort and a ~974-patient safety cohort, evaluating both IV and subQ administration; blinded treatment concluded June 2024 and topline is expected around H1 2026 [2][10]. The DIAN-TU-002 platform (NCT06647498, sponsored by Washington University) is a Phase 2/3 adaptive trial in carriers of dominantly inherited AD mutations, using amyloid PET centiloid change as the Stage 1 biomarker endpoint [3]. Lilly has also completed Phase 1 pharmacokinetic work in healthy volunteers (NCT07056309) and a bridging PK study in Chinese participants (NCT07346495) [5][6]. Early Phase 1 dose-ranging (700-2800 mg IV Q4W) reported 75% (18/24) of participants reaching amyloid clearance below 24.1 centiloids by day 169, which is what justified the aggressive Phase 3 timeline [11]. No breakthrough therapy, fast track, or accelerated approval designations have been publicly disclosed for remternetug. The most commercially meaningful readout is whether subQ dosing produces the same rapid amyloid clearance seen with IV donanemab in TRAILBLAZER-ALZ 2, which would let Lilly move Kisunla-class therapy out of the infusion suite entirely [1].

Amyloid beta is a sticky protein fragment that clumps into plaques between neurons in Alzheimer's brains. Remternetug binds a specific chewed-up version of it called N3pG-Aβ (pyroglutamate-modified amyloid beta), which is only found in mature plaques, not in healthy soluble amyloid floating around the brain [1][7]. That selectivity is the design trick: the antibody ignores the normal protein and only chases the deposited garbage, then recruits microglia (the brain's cleanup cells) to eat the plaques. This is exactly how donanemab works, and donanemab already showed 35% slowing of cognitive decline in TRAILBLAZER-ALZ 2, leading to Kisunla's 2024 approval [8]. So the mechanism is validated at the target level. Plaque burden is measured in centiloids, a standardized amyloid PET unit where a score near 0 is essentially plaque-free and Alzheimer's patients typically score above 50; regulatory-relevant clearance thresholds sit below about 24.1 centiloids. What's unresolved is whether stripping plaques out of asymptomatic or genetically-loaded brains actually prevents dementia, or just delays it by a year or two. The amyloid hypothesis has survived Aduhelm, been vindicated by Leqembi and Kisunla, but the effect sizes remain modest relative to the disease's brutality [9].

The lead trial in this node, NCT06647498, is the DIAN-TU-002 (Dominantly Inherited Alzheimer Network Trials Unit) remternetug arm, a Phase 2/3 adaptive study run by Washington University in participants who carry PSEN1, PSEN2, or APP mutations that cause early-onset dominantly inherited AD [3]. Stage 1 enrolls 280 participants and uses amyloid PET centiloid change as the primary biomarker endpoint, with progression to Stage 2 gated on hitting predefined amyloid reduction thresholds. Population selection is exceptionally clean: mutation carriers develop AD with near-100% penetrance at predictable ages, which is why DIAN-TU has been the reference platform for prevention biology since 2012. TRAILRUNNER-ALZ 1 (NCT05463731) is the commercially decisive study: Phase 3 in early symptomatic AD, ~1,667 participants total, primary endpoint amyloid plaque clearance on PET versus placebo [2]. That endpoint is a surrogate, but FDA has accepted amyloid clearance as the basis for accelerated approval in this class before. Blinded treatment on TRAILRUNNER-ALZ 1 completed June 2024; DIAN-TU-002 is still recruiting.

Our model estimates a 9% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by larger-than-typical enrollment for this phase and the sponsor's strong record of getting drugs approved; it is held back by heavier-than-usual blinding and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the amyloid hypothesis itself. Kisunla and Leqembi slow decline by roughly 27-35% over 18 months, which is meaningful but not disease-modifying in the way patients and payers want [8]. If remternetug in DIAN-TU-002 fails to translate amyloid clearance into cognitive or functional benefit in genetically-loaded carriers, that's a bigger problem for Lilly than losing one trial. Safety risk is ARIA (amyloid-related imaging abnormalities), the class-defining toxicity: microbleeds and brain swelling detected on MRI, occurring in roughly 25-35% of donanemab-treated patients and disproportionately in APOE4 homozygotes (carriers of two copies of the APOE4 gene, roughly 2-3% of the population, who face the highest Alzheimer's risk and the worst ARIA rates) [8]. Fatal ARIA cases have occurred with both Leqembi and Kisunla. Any signal that subQ dosing produces different ARIA kinetics (either better or worse) will define the label. Execution risk on TRAILRUNNER-ALZ 1 is low given blinded treatment complete, higher on DIAN-TU-002 which needs mutation-carrier recruitment. Commercial risk is the most underappreciated and has two axes. First, CMS coverage for the class is restrictive: Medicare requires clinician participation in the CMS registry (patient-level PET, MRI, cognitive-testing data) as a condition of reimbursement, which throttles rollout even after approval [12]. Second, remternetug enters a market where Eisai/Biogen's LEQEMBI IQLIK subcutaneous autoinjector (FDA-approved August 2025 for maintenance dosing at $19,500/year WAC, launched October 6, 2025; initiation-dose sBLA approved July 2026) already delivers at-home dosing in the anti-amyloid class [13][14]. Payers may not reimburse a third amyloid antibody without a clear cognitive or safety edge, even if convenience is comparable.

Worth watching, with a specific catalyst in sight. TRAILRUNNER-ALZ 1 topline is expected around H1 2026 per third-party trial trackers, likely presented at CTAD 2026 (late Q4) if timelines hold [10]. The signal to check for is the percentage of subQ-dosed patients reaching amyloid plaque clearance versus placebo, and the ARIA rate breakdown by APOE4 status. If subQ remternetug clears plaques as fast as IV donanemab did in TRAILBLAZER-ALZ 2 with a comparable or better ARIA profile, Lilly has the delivery advantage plus in-house infrastructure (Kisunla registry data, established prior-auth workflows) to defend the anti-amyloid market. If clearance is slower or ARIA is worse, this becomes a defensive follow-on rather than a franchise extension, especially with LEQEMBI IQLIK already commercial [13]. Context on market maturity: Kisunla itself is still a small franchise relative to hype, with Q1 2026 sales of $124M (roughly 5x year-over-year but well below Leqembi at similar tenure), so 'turning IV into subQ' is closer to a market-expansion play than a marginal improvement [15]. The DIAN-TU-002 data will take longer and matter more scientifically than commercially: it's the cleanest test of whether removing plaques from genetically-fated brains actually delays dementia. Lilly's $65B revenue base and Kisunla launch give this program more runway than most Phase 3 CNS assets get [4].